Teva and FTC reach settlement over ‘pay-for-delay’
Teva Pharmaceutical and the US Federal Trade Commission have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.
FDA publishes guidance on Competitive Generic Therapies
The US Food and Drug Administration has published new draft guidance on a pathway intended to boost the development of generics and lower drug prices.
SPC waiver stockpiling provision attracts criticism
While the final text of the European Council’s agreement on a supplementary protection certificate manufacturing waiver has yet to be released, the reported stockpiling provision has attracted criticism.
CJEU backs Warner-Lambert in marketing authorisation dispute
The Court of Justice of the European Union has issued a judgment in favour of Warner-Lambert amid a dispute between the American pharmaceutical company and an administrative body in the Netherlands.
J&J to buy surgical robotics company for $3.4bn
Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
European Council agrees on SPC manufacturing waiver
The European Council has reached a political agreement on a proposal for the supplementary protection certificate manufacturing waiver for patent-protected pharmaceuticals.
EU court rejects Bayer’s heart-related TM
Bayer suffered defeat at the hands of the EU General Court today, with the rejection of its attempt to register what the court deemed to be heart-related trademark.
Tough year ahead as generics take bite out of market: Teva
Israel-based Teva has predicted 2019 will be a tough year, with lower revenue and profit, as the company faces generic competition for two of its top-selling drugs.
EU court throws out dentistry TM application
The EU General Court has dismissed an appeal from German company Nemius Group against a decision to refuse registration for its ‘Dentaldisk’ mark.
Boehringer Ingelheim teams up with IBM to explore blockchain
The Canadian units of IBM and pharmaceutical company Boehringer Ingelheim have united to explore the use of blockchain technology in clinical trials.
